Investors’ outlook regarding the stock price performance over the year has been a mixed bag, with a range of optimism to pessimism depending on their perspective. Year to date metric has recorded a gain of 123.16%.However, over the last six months, we can see a weaker performance of 43.73%. Over the last 30 days, the price of AUTL has fallen by 68.92%. And in the last five days, it has surged by 14.59%.
Autolus Therapeutics plc ADR (AUTL) currently has a stock price of $4.24. The stock saw a sharp increase in the last trading session, hitting a high of $4.39 after opening at $4.00. The lowest recorded price for the day was $3.97 before it closed at $3.95.
The market performance of Autolus Therapeutics plc ADR has been somewhat stable. Over the past year, the company’s stock achieved a high of $4.11 on 11/15/23, with the lowest value for the same timeframe being $1.60, recorded on 12/12/22.
52-week price history of AUTL Stock
A stock’s 52-week price history, including the low and high prices, can offer valuable insights into its current standing and future prospects. Autolus Therapeutics plc ADR’s current trading price is 3.16% away from its 52-week high, while its distance from the 52-week low is 165.00%. The stock’s price range over this timeframe has been between $1.60 and $4.11. The shares of the Healthcare sector company recorded a trading volume of approximately 3.25 million for the day, which was comparatively higher than the average daily volume of 0.42 million over the last three months.
The Connection Between Financial Performance and Market Capitalization
Autolus Therapeutics plc ADR (AUTL) has experienced a quarterly rise of 44.22% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 737.51M and boasts a workforce of 399 employees.
Expert Opinions: Analysts’ Ratings for Autolus Therapeutics plc ADR
As of right now, 7 analysts are rating Autolus Therapeutics plc ADR as a BUY, 0 of the polled analysts branded the stock as an OVERWEIGHT, 2 analysts are recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.
How Moving Averages and Trading Volume Data Work Together
Based on Barchart.com data, the company’s moving average over the 100-day period was 2.84, with a change in price of +1.66. Similarly, Autolus Therapeutics plc ADR recorded 483,598 in trading volume during the last 100 days, posting a change of +64.34%.
AUTL’s Debt-to-Equity Ratio: A Comprehensive Review
A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for AUTL stands at 0.29. Similarly, the long-term debt-to-equity ratio is also 0.26.
AUTL Stock Stochastic Average
The raw stochastic average for Autolus Therapeutics plc ADR over the last 50 days is presently at 93.70%. This reflects a surge from the raw stochastic average of the previous 20 days, which was noted at 93.12%. Further, the company’s Stochastic %K and %D values for the last 20 days were 87.00% and 77.89%, respectively.